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Abstract 
Hypertensive diseases in pregnancy constitute a major concern and it is a major cause of maternal and perinatal 
morbidity and mortality worldwide and especially in the resource-challenged countries. Regimens for 
administration of magnesium sulphate have evolved over the years with different regimens being advocated.   
Objective: to compare the effectiveness of halve-dose regimen of magnesium sulphate therapy with standard 
Pritchard regimen in the management of patients with either pre-eclampsia or eclampsia. Result: out of 1,699 
deliveries recorded during the period of study 74 patients that met the inclusion criteria were recruited for this 
study 75.7% presented primarily with pre-eclampsia while 24.3% presented with eclampsia primarily. Booked 
patients were 52.7% while 47.3% were unbooked. There were two arms of this study; the standard Pritchard and 
the half-dose regimen arms. The standard Pritchard regimen arm had 36 subjects while the half-dose regimen 
had 38 subjects respectively. The same number of subjects in the two arms progressed from pre-eclampsia to 
eclampsia. There were more patients with recurrent convulsion in the standard Pritchard regimen arm compared 
to the half-dose regimen though this was not statistically significant.  
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Case fatality was 1.35% and it was due to HELLP syndrome. Neonatal admission and mortality were not 
significantly different between the two arms of the study. Patients’ satisfaction was generally more in the half-
dose regimen arm. Conclusion: from this study it is shown that giving half the dose of the standard Pritchard 
regimen is as effective as the standard Pritchard regimen itself. The import of this is that the risk of 
complications arising from magnesium sulphate is reduced, cost of treatment is also less, and overall general 
patient satisfaction is encouraging. 
Keywords: half-dose regimen; Pritchard regimen; eclampsia; pre-eclampsia; magnesium sulphate. 
1. Background 
Hypertensive diseases in pregnancy constitute major concern amongst Obstetricians. It is a major cause of 
maternal and perinatal morbidity and mortality worldwide, especially in low resource countries [1].    
Hypertension is common during pregnancy and around 10% of women will have their blood pressure recorded 
as above normal at some point during the antenatal period before delivery [2]. It is estimated to complicate 
about 5% of all pregnancies and 11% of first pregnancies [3]. Pre-eclampsia is defined as hypertension and 
significant proteinuria beginning during the second half of gestation in a previously normotensive and non-
proteinuric pregnant woman [3,4]. It complicates 4-8% of all pregnancies [5,6]. Eclampsia on the other hand, is 
the new onset of grand mal seizures occurring during or after pregnancy that do not have another identifiable 
cause [7,8].  It could also be defined as the development of convulsions and/or unexplained coma during 
pregnancy or postpartum in patients with signs and symptoms of pre-eclampsia [9]. Incidence of eclampsia in 
developed countries ranges from 5 to 7 cases per 10,000 deliveries [10], quite unlike in developing countries 
where Nigeria belongs, where the prevalence ranges from 2 to 16.7% [11-13].  Pre-eclampsia and eclampsia are 
not distinct disorders but the manifestation of the spectrum of clinical symptoms of the same condition [10]. 
Once eclampsia occurs the risk to mother and foetus[es] is substantial. The World Health Organization (WHO) 
estimates that the incidence of pre-eclampsia is seven times higher in the low and middle –income countries 
than in high-income countries, and the risk of a woman in a low-income country dying from either pre-
eclampsia or eclampsia is three hundred times that of a woman in a high-income country [7,14]. 
  Globally, pre-eclampsia and eclampsia account for 10-15% of maternal deaths [15]. Unlike in the developed 
countries where pre-eclampsia and eclampsia are associated with near-miss rather than maternal death, death 
usually results from eclampsia in the developing countries [16]. 
To date, the aetiology of pre-eclampsia has remained poorly understood but it has been documented that pre-
eclampsia is polygenetic and is caused by a combination of maternal and foetal genes with influence of 
environmental factors [17]. Pathogenesis of eclamptic convulsions has also remained source of controversy [9]. 
Magnesium sulphate was one of the earliest drugs suggested to have specific anticonvulsant action in the 
treatment of eclampsia[18]. Regimens for administration of magnesium sulphate have evolved over the years, 
but have not yet been formally evaluated [18]. Different regimens have been advocated by different experts in 
different countries [1,2,19,20]. Incidentally advocates for lower doses and shorter duration of treatment regimen 
have been more in the low resource countries where the cost of purchase of magnesium sulphate constitute a 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2019) Volume 44, No  2, pp 125-134 
127 
 
large chunk of the total cost of treating pre-eclampsia and/or eclampsia [18,19]. The great concern for 
magnesium sulphate therapy is the risk of the toxicity which could increase with duration of treatment and dose 
especially if monitoring of patient is suboptimal [19]. Average cost of an ampoule of 50% magnesium sulphate 
in a private hospital in Nigeria may be beyond the reach of most people and with standard Pritchard regimen 
where a patient will require minimum of 45g of magnesium sulphate before discharge, the cost is better 
imagined for an already impoverished populace, likewise the intramuscular route can cause so much pain even 
though the ease of administration cannot be over-looked, therefore less dose of intramuscular injection is 
tantamount to less pain and patient’s satisfaction.    
The exact mechanism of action of magnesium sulphate is unclear [2,19]. It may cause vasodilatation and 
subsequent reduction of cerebral ischaemia [21]. Alternatively it may have partial or total effect on N-methyl-D-
aspartate (NMDA) in the brain [2]. These NMDA receptors are activated in response to asphyxia, leading to 
calcium influx into the neurons, which causes cell injury [2]. It is suggested that magnesium may block these 
receptors, so reducing calcium influx thereby protecting the neurons from damage [2]. The objective of this 
study was to compare the effectiveness of halve-dose regimen of magnesium sulphate therapy with the standard-
dose Pritchard regimen in the management of patients with either pre-eclampsia or eclampsia 
1.1 Methodology  
This study was a prospective single-blind randomized study that spanned over a 12month period starting from 
January 1st  2017 to December  31st 2017 in the Obstetrics and Gynaecology unit of Sacred Heart Hospital, 
Lantoro, Abeokuta in Ogun State. The hospital is a 300 bedded hospital with the Obstetrics and Gynaecology 
unit having 88beds in various parts of the department. The hospital is the first hospital in Nigeria with clienteles 
from the whole of the South-West of Nigeria as well as the Republic of Benin.  All consenting pregnant women 
that had pre-eclampsia or eclampsia from 28weeks in our environment who presented to the antenatal clinic 
during the antenatal period, in labour or postpartum and who met the inclusion criteria were recruited into the 
study. However, patients with multiple gestation, renal disease or diabetes mellitus, those who already had 
magnesium sulphate therapy before presentation, and those that declined to participate were excluded from the 
study. At presentation each patient or her relative picked a sealed unlabeled envelope that contained either 
standard dose regimen or half dose regimen slip. This enabled the attending midwife or doctor to know the 
regimen to use for the patient. This was done after consent was obtained. A written informed consent was 
obtained from both the patients that were conscious and the relatives of those that were not conscious enough 
following which a designed pro-forma was used to obtain necessary information that was relevant to the study.  
For the purpose of this study significant hypertension and proteinuria were as defined by the International 
Society for the Study of Hypertension in Pregnancy (ISSHP), which are blood pressure of ≥140/90mmHg and 
proteinuria of ≥2+respectively. Korotkoff phase V was used to designate the diastolic blood pressure. At 
presentation at the clinics, antenatal ward, labour ward, or the postnatal ward the blood pressure of each subject 
was taken in the supine position with a left lateral tilt using an Accoson table-top mercury sphygmomanometer 
that had the appropriate size cuff with the arm at the level of the heart. The mid-stream urine sample obtained 
was tested with combi-9 urinalysis strip for proteinuria to make a diagnosis of pre-eclampsia or eclampsia. 
Height was measured with each subject standing barefooted on a standard Seca Stadiometer. The height was 
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read from under the head piece on the calibrated meter of the stadiometer to the nearest 0.1cm. Weight was 
measured using a calibrated weighing scale (Camry digital weighing scale) without shoes and subjects wearing 
light clothes; weight was read to the nearest 0.1kg. All these were done at presentation for those who were 
conscious while the measurements of those that presented in a state of unconsciousness were done after they had 
regained consciousness. Before discharge the satisfaction of each patient was assessed using “Short Assessment 
of Patient’s Satisfaction” tool was used. Analysis of data was done with Statistical Package for Social Science 
Students (SPSS) version 21. 
1.2 Primary outcomes 
• Eclampsia for those with pre-eclampsia, or recurrent convulsion for those with eclampsia 
• Death of baby before discharge from the hospital 
1.3 Secondary outcomes 
• Maternal death 
• Admission and length of stay in the hospital 
• Admission and length of stay in the special care baby unit (SCBU) 
2. Results    
  During the course of this study which was between January 1st 2017 and December 31st 2017 the unit recorded 
1,699 deliveries out of which 74 patients were either managed for pre-eclampsia or eclampsia using the standard 
Pritchard regimen or half-dose regimen. As depicted in table 1, 39(52.7%) of the patients were booked while 
35(47.3%) were unbooked. Ages of 25 to 29years accounted for 31.1% while those that were 40years and above 
accounted for 6.8%. 29.7% were primipara, 25.7% were primigravidae, and 5.4% were grandmultipara. 45.9% 
were between the gestational age of 38 and 42weeks; and only 18.9% presented at the gestational age of 28 to 
32weeks. Figure 1 shows the diagnosis at presentation; out of the 74 patients that were recruited for this study 
56(75.7%) had pre-eclampsia at presentation while 18(24.3%) had eclampsia at presentation. Figure 2 shows 
patient distributions in the two arms of the study; in the Pritchard regimen 10 patients had eclampsia at 
presentation while the remaining 26 patients had pre-eclampsia; in the half-dose regimen arm 8 patients had 
eclampsia primarily while the remaining 30 had pre-eclampsia at presentation. Table 2 shows the number of 
patients with pre-eclampsia in the Pritchard regimen arm and the Half-dose regimen arm that progressed to 
eclampsia to be equal; this finding was shown not to be statistically significant. The table 3 displays the number 
of patients in the two arms of the study that had recurrent convulsion despite therapy, there was no statistical 
significance between the two groups. The only maternal mortality recorded was in the Pritchard regimen arm as 
shown in table 4 making the case fatality rate to be 1.35%. Table 5 shows that 15 neonates were admitted into 
the neonatal intensive care unit in the Pritchard regimen arm while in the half-dose regimen arm 18 neonates 
were admitted into the neonatal intensive care unit with no statistically significant relationship. Figure 3 shows 
the number of neonatal deaths in the Pritchard regimen as well as those that occurred in the half-dose regimen 
arm with no statistically significant relationship. The duration of admission as depicted in table 6 showed that in 
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the Pritchard regimen arm 12 patients spent 4days or less on admission while 24 patients spent more than 4days 
while in the half-dose regimen arm 15 patients spent 4days or less on admission and 23 patients spent more than 
4days on admission with statistically significant relationship and there was no statistically significant 
relationship. Table 7 revealed that 25 patients expressed excellent satisfaction with the half-dose regimen 
compared to only 7patients in the Pritchard regimen arm; only a patient was indifferent to the half-dose regimen 
compared to none in the Pritchard regimen arm. 
Table 1: Sociodemographic characteristics of subjects 
 N=74 Percentage (%) 
Booking status   
Booked  39 52.7 
Unbooked  35 47.3 
Age range   
15-19 2 2.7 
20-24 12 16.2 
25-29 23 31.1 
30-34 21 28.4 
35-39 11 14.9 
≥40 5 6.8 
Parity    
0 19 25.7 
1 22 29.7 
2 17 23.0 
3 8 10.8 
4 4 5.4 
≥5 4 5.4 
Gestational age   
28-32 14 18.9 
33-37 26 35.1 
38-42 34 45.9 
 
 
Figure 1: Diagnosis at presentatiuon 
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Figure 2: Chart showing the number of subjects in the tow arms of the investigation 
Table 2: Number of patients with pre-eclampsia that developed eclampsia while on either Pritchard or half dose 
regimen 
 Yes  None     X2 
 
Regimen 
Pritchard  7  29  
   0.013 
Half dose 7 31 
Total  14 60 
Table 3: Number of patients with eclampsia on either Pritchard or half dose regimen that had recurrent 
convulsions 
 Yes  None  X2 
 
Regimen  
Pritchard  10 26  
2.445 
Half dose 5 33 
Total 15 59 
Table 4: Maternal mortality compared against the regimen used 
   Yes None 
 
Regimen 
Pritchard  1 35 
Half dose  0 38 
Total  1 73 
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Table 5: Regimen compared to NICU neonatal admission 
      Yes  None  X2 
 
Regimen 
Pritchard  15 21  
0.243 
Half dose 18 20 
Total  33 41 
 
Figure 3: Neonatal mortality compared against the regimen used in the two arms of the study 
X2 = 0.538 
Table 6: Regimen compared to duration 
                                                            Duration of hospital stay 
 
 
Regimen 
      ≤4 days     >4days Total  X2 
Pritchard       12      24    36  
0.301 
Half dose       15      23    38 
Total        27      47    74 
 
Table 7: Regimen against patients’ satisfaction 
   Excellent  Very good    Good  Not good Indifferent 
 
Regimen 
Pritchard          7        13       13       3        0 
Half-dose       25        10         2       3        0 
Total        32        23       15       6        0 
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3. Discussion 
During the period of study the department recorded 1,699 deliveries out of which 18 of them had eclampsia 
while 56 patients had pre-eclampsia, this makes the incidence of eclampsia and pre-eclampsia to be 1.06% and 
3.3% respectively. The incidence of eclampsia is low compared to findings in most studies carried out in public 
institutions in Nigeria, however the incidence of pre-eclampsia is comparable to the findings in some public 
health institutions in the country [17, 19, 20, 22], the reason for these disparities could be because of the 
likelihood of presentation in other private or public health facilities.  
Interestingly it is said that PET/eclampsia is often associated with primigravidity the findings of this study say 
otherwise for the patients with one and two previous deliveries were more than the primigravidae, the reason for 
this is not clear-cut; this finding might have been influenced by environmental or dietary factors [17] though 
these were not part of this present study.  
It is without prejudice that magnesium sulphate is very effective in preventing eclampsia in patients with pre-
eclampsia and recurrent convulsions in the eclamptics. In the two arms of this study the number of patients that 
progressed to eclampsia from pre-eclampsia is the same; this goes to show that development of convulsion may 
be independent of the dose of magnesium sulphate administered to a patient, also compared to the Pritchard 
regimen arm there were less number of patients that developed recurrent convulsion in the half-dose regimen 
though the finding was not statistically significant. The import of these findings are: (i) less dose of the 
magnesium sulphate may be needed to either treat pre-eclampsia or prevent eclampsia thereby reduction in the 
cost of treatment, (ii) the risk of complications that may arise from magnesium sulphate therapy will be 
remarkably reduced.  
There was only one maternal mortality recorded making the case fatality rate to be 1.35% this is rather lower 
than the findings by other authors in public institutions [7,12,19,20]. This death occurred in the Pritchard 
regimen arm however this does not imply magnesium sulphate caused the death because the patient died as a 
result of HELLP syndrome. Ironically there were more neonatal death in the Pritchard arm of the study, it is 
difficult to adduce that the dose of the magnesium sulphate could have accounted for this without taking into 
consideration the primary disease itself which can lead to either maternal or neonatal morbidity/mortality.  
 Compared to Pritchard regimen patients were generally more satisfied in the half-dose regimen arm using the 
Short Assessment of Patient Satisfaction (SAPS) developed by the center for Health Service Development of 
University of Wollongong [24]. 
4. Conclusion  
The study revealed that giving half the dose of the standard Pritchard regimen is as effective as the standard 
Pritchard regimen itself. The import of this is that the risk of complications arising from magnesium sulphate 
therapy is reduced, cost of treatment is also less, and overall general patient satisfaction is encouraging.      
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5. Constraints/limitations  
 The sample size was too small to draw a conclusion that half-dose magnesium sulphate regimen is as effective 
as the standard dose regimen however, with proper patient selection a lot of benefits could be derived from half-
dose regimen. It was difficult to determine the accuracy of the gestational age in the unbooked patients since 
they did not have the benefit of having an early ultrasound scan.  
6. Recommendation 
Giving halve the dose of the standard Pritchard regimen that is normally required traditionally is as effective as 
the standard regimen with less cost and better patient’s satisfaction. It will also prevent some of the 
complications associated with magnesium sulphate since the safety margin of the drug is small. A larger 
multicenter study may be required before an outright recommendation for the use of half dose regimen.   
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